A new pathway towards immunotherapy-supported radiology for targeted Boron Neutron Capture Therapy (BNCT)

Main Article Content

Klaus M. Spohr
Gabriel P. Bleotu
Mirabela Cristea
Domenico Doria
Alexandra Ivan
Marius Jurca
Vincent Lelasseux
Cristina Marin
Viorel Nastasa
Valentin Ordodi
Virgil Paunescu
Mara Popovici
Silviu Stanciu
Stefan Stoenescu
Calin Tatu
Ada Telea
Chieh-jen Yang
Maria-Iulia Zai

Abstract

Background: We present our novel, patented paradigm of immunotherapy-supported radiology designed to augment conventional FDA-approved Boron Neutron Capture Therapy (BNCT). This innovative approach employs immunocompetent cells as vectors for boron nanoparticles, thereby facilitating targeted radiological treatment. Our methodology addresses the evasive propensity of ’cold’ solid tumors, which often remain undetected due to their integration within fibroblast-rich micro environments devoid of distinct markers.


Methods: By loading boron into immunocompetent cells, these entities function as highly selective delivery agents—akin to nanorobots—capable of transporting therapeutically sufficient payloads (80 µg/tumor) of the stable isotope 10B directly into malignant cells or their immediate vicinity, priming them for BNCT. The subsequent treatment method involves exposing the patient to a relatively benign beam of low-energy, ’epithermal’ neutrons (En ∼ 0.025 eV) generated by a compact particle accelerator. The therapeutic efficacy hinges on the nuclear reaction 10B + n → 4He +7Li, which occurs with a high cross-section and is impervious to any tumor-supporting microenvironment. The energy released via Linear Energy Transfer (LET) by the resultant lithium and helium ions is confined to a cellular scale (~9 µm), inducing apoptosis with remarkable precision. Hallmark: This spatially restricted energy deposition minimizes collateral damage to adjacent healthy tissue, the hallmark aim of our approach. Our patented boron-loading mechanism employing liposome-mediated endocytosis enables the incorporation of approximately 109 boron atoms into a single immunocompetent cell without compromising its biological functionality. In vitro experiments conducted at the neutron-providing nuclear reactor at the ICN in Pitesti corroborate the immense potential of this immunotherapy-supported BNCT paradigm.


Conclusion: We conclude that this pioneering strategy can potentially become a transformative advancement in targeted oncological therapies of recalcitrant solid tumors.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Spohr KM, Bleotu GP, Cristea M, Doria D, Ivan A, Jurca M, et al. A new pathway towards immunotherapy-supported radiology for targeted Boron Neutron Capture Therapy (BNCT). SEE J Immunol [Internet]. 2025 Mar. 25 [cited 2026 Nov. 17];8(CITIM):057. Available from: https://seejim.eu/index.php/seejim/article/view/6128
Section
Invited lectures

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.